{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:42:44Z","timestamp":1775706164310,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jcf.2023.01.012","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:26:47Z","timestamp":1675358807000},"page":"263-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8975-695X","authenticated-orcid":false,"given":"Carla","family":"Colombo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant A","family":"Ramm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-1876","authenticated-orcid":false,"given":"Anders","family":"Lindblad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Corti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3172-6528","authenticated-orcid":false,"given":"Luigi","family":"Porcaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-791X","authenticated-orcid":false,"given":"Federico","family":"Alghisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Asherova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliya","family":"Kashirskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6395-0407","authenticated-orcid":false,"given":"Elena","family":"Kondratyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J","family":"Lewindon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9503-657X","authenticated-orcid":false,"given":"Isabelle","family":"de Monestrol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee Y.","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-8125","authenticated-orcid":false,"given":"Rita","family":"Padoan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahana","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Alicandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.01.012_bib0001","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis phe508del gating and residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.01.012_bib0002","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2023.01.012_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.01.012_bib0004","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.01.012_bib0005","first-page":"1769","article-title":"CFTR modulators in people with cystic fibrosis","volume":"11","author":"Regard","year":"2022","journal-title":"Real-World Evid France Cells"},{"key":"10.1016\/j.jcf.2023.01.012_bib0006","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in patients with cystic fibrosis and one or two f508del alleles","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.01.012_bib0007","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.510300527","article-title":"Natural history of liver disease in cystic fibrosis","volume":"30","author":"Lindblad","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jcf.2023.01.012_bib0008","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MPG.0000000000001728","article-title":"Variceal hemorrhage and adverse liver outcomes in patients with cystic fibrosis cirrhosis","volume":"66","author":"Ye","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2023.01.012_bib0009","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jcf.2021.03.014","article-title":"Ursodeoxycholic acid and liver disease associated with cystic fibrosis","volume":"21","author":"Colombo","year":"2022","journal-title":"A Multicenter Cohort Study J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.01.012_bib0010","unstructured":"Trikafta - Highlights of prescribing information. https:\/\/pi.vrtx.com\/files\/uspi_elexacaftor_tezacaftor_ivacaftor.pdf (accessed June 20, 2022)."},{"key":"10.1016\/j.jcf.2023.01.012_bib0011","unstructured":"Clinical and Functional Translation of CFTR. https:\/\/cftr2.org\/(accessed June 20, 2022)."},{"key":"10.1016\/j.jcf.2023.01.012_bib0012","unstructured":"Cystic Fibrosis Foundation. 2021 Cystic Fibrosis Foundation Patient Registry Highlights 2022. https:\/\/www.cff.org\/medical-professionals\/patient-registry (accessed October 13, 2022)."},{"key":"10.1016\/j.jcf.2023.01.012_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106878","article-title":"Who are the 10%? - non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies","volume":"199","author":"Desai","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2023.01.012_bib0014","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.transproceed.2018.11.007","article-title":"Unusual cystic fibrosis transmembrane conductance regulator mutations and liver disease: a case series and review of the literature","volume":"51","author":"Khan","year":"2019","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jcf.2023.01.012_bib0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/17476348.2018.1483723","article-title":"Unmet needs in cystic fibrosis: the next steps in improving outcomes","volume":"12","author":"West","year":"2018","journal-title":"Expert Rev Respir Med"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:48:19Z","timestamp":1761601699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1569199323000206"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.01.012","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}